1.Clinical Efficacy of Tangning Tongluo Tablets for Nonproliferative Diabetic Retinopathy
Fuwen ZHANG ; Junguo DUAN ; Wen XIA ; Tiantian SUN ; Yuheng SHI ; Shicui MEI ; Xiangxia LUO ; Xing LI ; Yujie PAN ; Yong DENG ; Chuanlian RAN ; Hao CHEN ; Li PEI ; Shuyu YANG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(3):132-139
ObjectiveTo observe the clinical efficacy and safety of Tangning Tongluo tablets in the treatment of nonproliferative diabetic retinopathy (DR). MethodsFourteen research centers participated in this study, which spanned a time interval from September 2021 to May 2023. A total of 240 patients with nonproliferative DR were included and randomly assigned into an observation group (120 cases) and a control group (120 cases). The observation group was treated with Tangning Tongluo tablets, and the control group with calcium dobesilate capsules. Both groups were treated for 24 consecutive weeks. The vision, DR progression rate, retinal microhemangioma, hemorrhage area, exudation area, glycosylated hemoglobin (HbA1c) level, and TCM syndrome score were assessed before and after treatment, and the safety was observed. ResultsThe vision changed in both groups after treatment (P<0.05), and the observation group showed higher best corrected visual acuity (BCVA) than the control group (P<0.05). The DR progression was slow with similar rates in the two groups. The fundus hemorrhage area and exudation area did not change significantly after treatment in both groups, while the observation group outperformed the control group in reducing the fundus hemorrhage area and exudation area. There was no significant difference in the number of microhemangiomas between the two groups before treatment. After treatment, the number of microhemangiomas decreased in both the observation group (Z=-1.437, P<0.05) and the control group (Z=-2.238, P<0.05), and it showed no significant difference between the two groups. As the treatment time prolonged, the number of microhemangiomas gradually decreased in both groups. There was no significant difference in the HbA1c level between the two groups before treatment. After treatment, the decline in the HbA1c level showed no significant difference between the two groups. The TCM syndrome score did not have a statistically significant difference between the two groups before treatment. After treatment, neither the TCM syndrome score nor the response rate had significant difference between the two groups. With the extension of the treatment time, both groups showed amelioration of TCM syndrome compared with the baseline. ConclusionTangning Tongluo tablets are safe and effective in the treatment of nonproliferative DR, being capable of improving vision and reducing hemorrhage and exudation in the fundus.
2.Network meta-analysis for efficacy and safety of aromatase inhibitors for postmenopausal hormone receptor-positive early breast cancer
Yujie LI ; Wenjing ZHANG ; Hongxin YANG ; Hao GUO
China Pharmacy 2025;36(12):1520-1524
OBJECTIVE To evaluate the efficacy and safety of three aromatase inhibitors (exemestane, anastrozole, letrozole) for postmenopausal hormone receptor (HR)-positive early breast cancer. METHODS PubMed, the Cochrane Library, Embase, CNKI, Wanfang Data, VIP and SinoMed were searched to collect randomized controlled trials (RCTs) of the above three drugs in the treatment of postmenopausal HR-positive early breast cancer patients. The retrieval time limit was from the establishment of the database to October 25, 2024. After literature screening, data extraction and literature quality evaluation, network meta-analysis was performed by using RevMan 5.3 and Stata 18.0 software. RESULTS A total of 15 RCTs involving 44 055 patients were included. The results of network meta-analysis showed that the objective response rate of letrozole group was significantly higher than anastrozole group (P<0.05), and the order of surface under the cumulative ranking curve (SUCRA) from high to low was letrozole (85.6%)>anastrozole (61.5%)>exemestane (2.8%). The disease-free survival rate of anastrozole group was significantly higher than exemestane and placebo groups (P<0.05), and the order of SUCRA from high to low was letrozole (85.8%)> anastrozole (67.3%)>exemestane (41.4%)>placebo (5.5%). The total incidence of adverse reactions in anastrozole group was significantly higher than letrozole and placebo groups (P<0.05), and the order of SUCRA from high to low was exemestane (87.4%)>letrozole (63.9%)>anastrozole (47.0%)>placebo (1.7%). The results of subgroup analysis according to the course of treatment≥104 weeks were consistent with them. CONCLUSIONS Compared with anastrozole, letrozole has better efficacy and safety in the treatment of postmenopausal HR-positive early breast cancer, and the efficacy of exemestane is limited.
3.Corrigendum to "Hydralazine represses Fpn ubiquitination to rescue injured neurons via competitive binding to UBA52" J. Pharm. Anal. 14 (2024) 86-99.
Shengyou LI ; Xue GAO ; Yi ZHENG ; Yujie YANG ; Jianbo GAO ; Dan GENG ; Lingli GUO ; Teng MA ; Yiming HAO ; Bin WEI ; Liangliang HUANG ; Yitao WEI ; Bing XIA ; Zhuojing LUO ; Jinghui HUANG
Journal of Pharmaceutical Analysis 2025;15(4):101324-101324
[This corrects the article DOI: 10.1016/j.jpha.2023.08.006.].
4.A prospective study on association between sleep duration and the risk of chronic obstructive pulmonary disease in adults in Suzhou
Mengshi YANG ; Xikang FAN ; Jian SU ; Xinglin WAN ; Hao YU ; Yan LU ; Yujie HUA ; Jianrong JIN ; Pei PEI ; Canqing YU ; Dianjianyi SUN ; Jun LYU ; Ran TAO ; Jinyi ZHOU
Chinese Journal of Epidemiology 2024;45(3):331-338
Objective:To investigate the prospective association of sleep duration with the development of chronic obstructive pulmonary disease (COPD) in adults in Suzhou.Methods:The study used the data of 53 269 participants aged 30-79 years recruited in the baseline survey from 2004 to 2008 and the follow-up until December 31, 2017 of China Kadoorie Biobank (CKB) conducted in Wuzhong District, Suzhou. After excluding participants with airflow limitation, self-reported chronic bronchitis/emphysema/coronary heart disease history at the baseline survey and abnormal or incomplete data, a total of 45 336 participants were included in the final analysis. The association between daily sleep duration and the risk for developing COPD was analyzed by using a Cox proportional hazard regression model, and the hazard ratio ( HR) values and their 95% CI were calculated. The analysis was stratified by age, gender and lifestyle factors, and cross-analysis was conducted according to smoking status and daily sleep duration. Results:The median follow-up time was 11.12 years, with a total of 515 COPD diagnoses in the follow-up. After adjusting for potential confounders, multifactorial Cox proportional hazard regression analysis showed that daily sleep duration ≥10 hours was associated with higher risk for developing COPD ( HR=1.42, 95% CI: 1.03-1.97). The cross analysis showed that excessive daily sleep duration increased the risk for COPD in smokers ( HR=2.49, 95% CI: 1.35-4.59, interaction P<0.001). Conclusion:Longer daily sleep duration (≥10 hours) might increase the risk for COPD in adults in Suzhou, especially in smokers.
5.Effects of 2 650 MHz radiofrequency radiation on the behavior and hippocampal neurotransmitter release of mice
Yujie LIU ; Jun WANG ; Keqin LI ; Chenxu CHANG ; Ying LIU ; Hongyan ZUO ; Yang LI ; Hong YANG ; Yanhui HAO ; Hua DENG
Chinese Journal of Radiological Medicine and Protection 2024;44(5):354-360
Objective:To investigate the effects of 2 650 MHz radiofrequency (RF) exposure on the behavior and neurotransmitter release of mice.Methods:Adult male C57BL/6N mice were divided into a normal control (CON) group and a radiofrequency radiation (RFR) group using the random number table method. The mice in the RFR group were subjected to single-dose whole-body exposure to a uniform 2 650 MHz RF electromagnetic field for 3 h. During the RF exposure, the field strength in the effective working area of the RF radiation platform was measured using an electromagnetic radiation analyzer, and the changes in the anal temperature of the mice were monitored using an optical fiber thermometer. Moreover, the changes in the cognition, social interaction, and emotion of the mice were determined through the new object recognition test, social preference test, and open field test. Finally, the changes in the hippocampal neurotransmitter release levels of the mice were detected using microdialysis sampling and mass spectrometry, and the changes in the hippocampal tissue structure and ultrastructure were observed via microscopy.Results:Under the test conditions, RF radiation improved the anal temperature of the mice, with a maximum increasing amplitude of 0.61℃, falling within the range of thermal safety. The mice in the RFR group experienced a significant decrease in the frequency and time for exploring new objects ( t=4.50, 2.53, P < 0.05) in the new object recognition test, a significant decrease in the frequency ( t=0.08, P<0.01) and time ( t=0.03, P<0.05) for exploring other mice in the social preference test, and no significant change in the frequency and time for exploring the central area ( P > 0.05) in the open field test. Compared to the CON group, the RFR group showed an increase in the release of 5-hydroxytryptamine (5-HT) ( t=-2.56, P < 0.05) and a decrease in the release of acetylcholine (ACh) ( t=2.21, P < 0.05), no significant difference in the release of glutamate (Glu) and γ-aminobutyric acid (GABA) ( P > 0.05), and no evident damage to the hippocampal tissue and structure and synaptic ultrastructure. Conclusions:2 650 MHz RF radiation may induce cognitive impairment and abnormal social preference in mice, which is attributed to neuronal dysfunctions and neurotransmitter release disorders under RF exposure.
6.Research on bed efficiency in public hospitals under DRG background
Yujie ZHANG ; Hao XU ; Ao ZOU ; Li XU ; Rong HU ; Chenhui LIU
Modern Hospital 2024;24(7):1066-1069,1074
Objective To analyze the bed utilization efficiency of various clinical departments in a public hospital and provide reference for the rational allocation of departmental bed resources.Methods Based on the data from a tertiary specialized hospital in 2022,traditional bed efficiency indicators were used as the basis.The Case Mix Index(CMI)was introduced for ad-justment,and the reasonable range of beds for each department was calculated.Data Envelopment Analysis(DEA)was em-ployed to comprehensively evaluate the input-output efficiency of each clinical department and determine the direction for optimi-zing bed allocation.Results Among the 39 departments included in the study,10 departments had inappropriate bed settings.Among them,5 departments needed additional beds,while 5 departments needed to reduce the number of beds.Conclusion By adjusting the bed efficiency indicators using CMI and combining the DEA method,hospitals can obtain a scientific basis for dy-namically adjusting the number of beds in clinical departments.Hospitals should make rational use of bed resources and scientifi-cally plan departmental beds.
7.Efgartigimod alfa in the treatment of generalized myasthenia gravis:a rapid health technology assessment
Gerile HUANG ; Yujie LI ; Wenjing ZHANG ; Hao GUO
Chinese Journal of Pharmacoepidemiology 2024;33(10):1156-1163
Objective To evaluate the efficacy,safety and economy of efgartigimod alfa in the treatment of generalized myasthenia gravis by rapid health technology assessment,and to provide evidence-based evidence for clinical rational drug use.Methods PubMed,Embase,Web of Science,Cochrane Library,CNKI,VIP,WanFang Data,SinoMed database and relevant databases of health technology assessment institutions were electronically searched to collect health technology assessment reports,systematic reviews/Meta-analysis and pharmacoeconomic literatures of efgartigimod alfa for the treatment of generalized myasthenia gravis from the inception to June 21,2024.Two researchers screened the literature,extracted data,and evaluated the quality of the literature,summarised the finding and performed qualitative descriptive analysis.Results A total of 6 literature were included,involving 5 systematic reviews/Meta-analysis and one pharmacoeconomic study.In terms of efficacy,efgartigimod alfa demonstrated a significant reduction in MG-ADL,QMGs,and MG-QOLs 15R compared to placebo among generalized myasthenia gravis patients,these differences were statistically significant(P<0.05).However,findings from different studies regarding comparisons with other biologics like batoclimab,ronzanolixizumab,and eculizumab yielded inconsistent conclusions.In terms of safety,the incidence of adverse events in adults generalized myasthenia gravis patients treated with efgartigimod alfa compared with that of the placebo was not statistically significant(P>0.05).However,compared with other biological agents,the conclusions drawn from each study were inconsistent.In terms of economics,efgartigimod alfa did not exhibit cost-effectiveness advantages over traditional therapies.Conclusion Efgartigimod alpha showed better efficacy than placebo in the treatment of generalized myasthenia gravis,but there was no definitive conclusion compared with other biological agents.In terms of safety,the incidence of ADE in adult generalized myasthenia gravis patients treated with efgartigimod alpha was not statistically different from that of the placebo group,and no definite conclusion could be drawn when compared with other biological agents.According to U.S.drug economic data,efgartigimod alpha does not have economic advantages over traditional therapies.
8.Mechanism of action of Polygonum multiflorum in inducing liver injury: A study based on signaling pathways
Zihan LIANG ; Jiahui LI ; Shuang CHENG ; Zhuoya YUAN ; Wenya RONG ; Yajie LIU ; Yujie HAO ; Ruilin WANG
Journal of Clinical Hepatology 2024;40(3):626-632
Polygonum multiflorum (PM), a commonly used Chinese herbal medicine in clinical practice, has been associated with frequent reports of liver injury in recent years, and the medication safety of PM has attracted more and more attention in China and globally. This article reviews the recent research advances in the signaling pathways and mechanisms of PM in causing drug-induced liver injury (DILI) and aims to provide new ideas for the proper and rational use of PM in clinical practice. The results show that PM is involved in the regulation of various signaling pathways, and it leads to the death of hepatocytes by destroying mitochondrial function, exacerbating bile acid accumulation, and inducing immune response, oxidative stress, and endoplasmic reticulum stress, thereby inducing the development and progression of DILI through multiple targets, pathways, and levels.
9.Fungal luminescence pathways: research and applications.
Yujie WU ; Jiarui XU ; Hongyu CHEN ; Hao DU
Chinese Journal of Biotechnology 2024;40(1):1-14
The fungal bioluminescence pathway (FBP) is a metabolic pathway responsible for the generation of bioluminescence derived from fungi. This pathway utilizes caffeic acid as the substrate, generating a high-energy intermediate, and the decomposition of which yields green fluorescence with a wavelength of approximately 520 nm. The FBP is evolutionally conserved in luminescent fungal groups. Unlike other bioluminescent systems, the FBP is particularly suitable for engineering applications in eukaryotic organisms, especially in plants. Currently, metabolically engineered luminescent plants are able to emit visible light to illuminate its surroundings, which can be visualized clearly in the dark. The fungal bioluminescent system could be explored in various applications in molecular biology, biosensors and glowing ornamental plants, and even green lighting along city streets.
Luminescence
;
Light
;
Fluorescence
;
Eukaryota
;
Green Light
10.Association between urinary thallium and nonalcoholic fatty liver disease
Yajie LIU ; Ruilin WANG ; Zihan LIANG ; Jiahui LI ; Yujie HAO
Journal of Clinical Hepatology 2024;40(4):688-693
ObjectiveTo investigate the association between urinary thallium (TL) and nonalcoholic fatty liver disease (NAFLD). MethodsRelated data were collected from the registered participants aged ≥18 years in National Health and Nutrition Examination Survey from 2017 to 2020, with th exclusion of the individuals with a lack of liver transient elastography data and urinary TL indicators and those with hepatitis B, hepatitis C or significant alcohol consumption. A total of individuals were divided into NAFLD group and non-NAFLD group. Urinary TL level was quantitatively measured using high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry and online solid-phase extraction combined with isotope dilution. The two groups were compared in terms of age, sex, race, marital status, education, family income poverty impact ratio (FMPIR), body mass index (BMI), smoking, alcohol consumption, diabetes mellitus (DM), hypertension (HTN), hyperlipidemia (HL), and urinary TL level. The independent-samples t test or the Wilcoxon rank-sum test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. Descriptive analysis, multivariable Logistic regression, restricted cubic spline regression analysis, subgroup analysis, and interaction analysis were conducted to investigate the risk association between urinary TL and NAFLD. ResultsA total of 2 511 individuals were included, with 1 612 (64.20%) in the NAFLD group and 899 (35.80%) in the non-NAFLD group, and the NAFLD group had a significantly higher urinary TL level than the non-NAFLD group [0.18 (0.11 — 0.26)μg/L vs 0.16 (0.09 — 0.25)μg/L, Z=-2.76, P=0.01]. After adjustment for the covariates of age, sex, race, education, marital status, FMPIR, BMI, smoking, alcohol consumption, DM, HTN, and HL, the urinary TL Q4 group had a significant increase in the risk of NAFLD (odds ratio [OR]=1.90, 95% confidence interval [CI]: 1.48 — 2.44, P<0.01). There was a positive dose-response relationship (P<0.01) and a non-linear relationship (P<0.01) between urinary TL and the risk of NAFLD. A significant interaction was observed between urinary TL and smoking/BMI (P<0.05). For individuals taking ≥100 cigarettes in their lifetime, the risk of NAFLD was increased by 50% for every quartile increase in urinary TL (OR=1.50, 95%CI: 1.24 — 1.80), and for individuals taking<100 cigarettes in their lifetime, the risk of NAFLD was increased by 20% for every quartile increase in urinary TL (OR=1.20, 95%CI: 1.03 — 1.40); for individuals with a BMI of ≥30 kg/m2, the risk of NAFLD was increased by 30% for every quartile increase in urinary TL (OR=1.30, 95%CI: 1.05 — 1.70), with a statistical significance (P<0.05). ConclusionUrinary TL level is significantly associated with the risk of NAFLD.

Result Analysis
Print
Save
E-mail